293 related articles for article (PubMed ID: 26566667)
1. Heart Failure and Mortality in Patients With Nonvalvular Atrial Fibrillation Started on Novel Oral Anticoagulant Therapy: A Single-Center Experience.
Sunbul M; Oguz M; Dogan Z; Atas H; Bozbay M; Cincin A; Agirbasli M
Clin Appl Thromb Hemost; 2017 Jul; 23(5):454-459. PubMed ID: 26566667
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
4. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
5. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
6. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant.
Brown LAE; Boos CJ
Int J Cardiol; 2017 Jan; 227():863-868. PubMed ID: 28029411
[TBL] [Abstract][Full Text] [Related]
8. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.
Russo V; Attena E; Mazzone C; Esposito F; Parisi V; Bancone C; Rago A; Nigro G; Sangiuolo R; D' Onofrio A
Semin Thromb Hemost; 2018 Jun; 44(4):364-369. PubMed ID: 29304513
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants and heart failure.
Isnard R; Bauer F; Cohen-Solal A; Damy T; Donal E; Galinier M; Hagège A; Jourdain P; Leclercq C; Sabatier R; Trochu JN; Cohen A
Arch Cardiovasc Dis; 2016 Nov; 109(11):641-650. PubMed ID: 27836786
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation.
Godino C; Bodega F; Melillo F; Rubino F; Parlati ALM; Cappelletti A; Mazzone P; Mattiello P; Della Bella P; Castiglioni A; Alfieri O; De Bonis M; Montorfano M; Tresoldi M; Filippi M; Zangrillo A; Salerno A; Cera M; Margonato A;
J Cardiovasc Med (Hagerstown); 2020 Oct; 21(10):751-758. PubMed ID: 32740435
[TBL] [Abstract][Full Text] [Related]
13. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW
Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation in atrial fibrillation with heart failure.
Zhao L; Wang WYS; Yang X
Heart Fail Rev; 2018 Jul; 23(4):563-571. PubMed ID: 29569146
[TBL] [Abstract][Full Text] [Related]
15. Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemiologic registry.
Kaya H; Ertaş F; Köroğlu B; Vatan B; Çağlıyan ÇE; Gedik S; Yeter E; Aydin M; Akil MA; Soydinç MS; Ozhan H; Ülgen MS;
Clin Appl Thromb Hemost; 2015 Mar; 21(2):144-8. PubMed ID: 23742948
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
17. Sex-Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation.
Palamaner Subash Shantha G; Mentias A; Inampudi C; Kumar AA; Chaikriangkrai K; Bhise V; Deshmukh A; Patel N; Pancholy S; Horwitz PA; Mickelsen S; Bhave PD; Giudici M; Oral H; Vaughan Sarrazin MS
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862952
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
19. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
Senoo K; Lane DA; Lip GY
Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
[TBL] [Abstract][Full Text] [Related]
20. Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation.
Vedovati MC; Verdecchia P; Giustozzi M; Molini G; Conti S; Pierpaoli L; Valecchi F; Aita A; Agnelli G; Becattini C
Int J Cardiol; 2017 Jun; 236():363-369. PubMed ID: 28131705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
